Proposed regulation would strip nursing home pharmacy providers of oversight duties

Share this article:
Proposed regulation would strip nursing home pharmacy providers of oversight duties
Proposed regulation would strip nursing home pharmacy providers of oversight duties
A proposed regulation that would require nursing homes to hire independent pharmacists to oversee residents' medication plan regimens could have a huge impact on pharmacy services suppliers such as Omnicare and PharMerica.  

According to the proposed rule, relationships between nursing homes and pharmacy suppliers could “conflict with the best interests of nursing home residents.” Therefore, the proposal to mandate independent pharmacists was made.  

The regulation also has implications for Omnicare's hostile takeover bid for rival PharMerica, according to observers.

News of the Centers for Medicare & Medicaid Services proposed rule made shares of Omnicare and PharMerica, the top two nursing home pharmacy suppliers, drop sharply Tuesday. Omnicare shares fell 12% to $21.62, while PharMerica's fell 15% to $11.91, Bloomberg News reported.

Omnicare announced Wednesday that it is extending its offer to purchase all outstanding shares of PharMerica until Dec. 2. Its previous offer was to expire at midnight Tuesday (Oct. 4).
Share this article:

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.